Vascular Disrupting Agents Market
完整報告名稱與涵蓋範圍
Vascular Disrupting Agents Market Size, Share & Trends Analysis Report By Indication, By Therapeutic Area (Hematological Malignancies, Solid Tumors), By Product, By Molecule, By Therapy, By Route of Administration, By Region, And By Segment Forecasts, 2029-2034.
報告摘要
Across the 2029 to 2034 projection horizon, the worldwide Vascular Disrupting Agents Market is expected to register a CAGR of 10%.
Vascular Disrupting Agents covers a novel family of medications that target the existing tumour vasculature and cause tumour necrosis. Rapid advancements and evolving end-user preferences are reshaping how healthcare entities approach this space.
The market's upward path is bolstered by growing healthcare spending, technological evolution, and the growing focus on personalized and precision-based approaches in healthcare.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, bolstered by rapid industrialization and expanding end-user bases.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Vascular Disrupting Agents Market Snapshot
Chapter 4. Global Vascular Disrupting Agents Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Indication, Estimates & Trend Analysis
5.1. By Indications, & Market Share, 2029 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Indications:
5.2.1. Chemotherapy-Induced Neutropenia
5.2.2. Glioblastoma
5.2.3. Liver Cancer
5.2.4. Mesothelioma
5.2.5. Non-Small Cell Lung Cancer
5.2.6. Prostate Cancer
5.2.7. Ovarian Cancer
5.2.8. Renal Pelvis
5.2.9. Ureter Cancer
Chapter 6. Market Segmentation 2: By Therapeutic Area Estimates & Trend Analysis
6.1. By Therapeutic Area & Market Share, 2029 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Therapeutic Area:
6.2.1. Hematological Malignancies
6.2.2. Solid Tumors
Chapter 7. Market Segmentation 3: By Molecule Estimates & Trend Analysis
7.1. By Molecule & Market Share, 2029 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Molecule:
7.2.1. Tubulin Binding Agents
7.2.2. Flavonoids
7.2.3. Ligand-Directed Agents
Chapter 8. Market Segmentation 4: By Therapy Estimates & Trend Analysis
8.1. By Therapy & Market Share, 2029 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Therapy
8.2.1. Mono
8.2.2. Combination
Chapter 9. Market Segmentation 5: By Route of Administrations Estimates & Trend Analysis
9.1. By Route of Administrations & Market Share, 2029 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Route of Administrations:
9.2.1. Oral
9.2.2. Intravenous
Chapter 10. Market Segmentation 6: By Products Estimates & Trend Analysis
10.1. By Products & Market Share, 2029 & 2034
10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
10.2.1. Bavituximab
10.2.2. Icaritin
10.2.3. NGR-TNF
10.2.4. Padeliporfin
10.2.5. Plinabulin
10.2.6. VB-111
10.2.7. Other Products
Chapter 11. Vascular Disrupting Agents Market Segmentation 7: Regional Estimates & Trend Analysis
11.1. North America
11.1.1. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts By Indications, 2021-2034
11.1.2. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
11.1.3. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts By Molecule, 2021-2034
11.1.4. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2021-2034
11.1.5. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
11.1.6. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2021-2034
11.1.7. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
11.2. Europe
11.2.1. Europe Vascular Disrupting Agents Market revenue (US$ Million) By Indications, 2021-2034
11.2.2. Europe Vascular Disrupting Agents Market revenue (US$ Million) By Therapeutic Area, 2021-2034
11.2.3. Europe Vascular Disrupting Agents Market revenue (US$ Million) By Molecule, 2021-2034
11.2.4. Europe Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2021-2034
11.2.5. Europe Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
11.2.6. Europe Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2021-2034
11.2.7. Europe Vascular Disrupting Agents Market revenue (US$ Million) by country, 2021-2034
11.3. Asia Pacific
11.3.1. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) By Indications, 2021-2034
11.3.2. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) By Therapeutic Area, 2021-2034
11.3.3. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) By Molecule, 2021-2034
11.3.4. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2021-2034
11.3.5. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
11.3.6. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2021-2034
11.3.7. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) by country, 2021-2034
11.4. Latin America
11.4.1. Latin America Vascular Disrupting Agents Market revenue (US$ Million) By Indications, (US$ Million) 2021-2034
11.4.2. Latin America Vascular Disrupting Agents Market revenue (US$ Million) By Therapeutic Area, (US$ Million) 2021-2034
11.4.3. Latin America Vascular Disrupting Agents Market revenue (US$ Million) By Molecule, (US$ Million) 2021-2034
11.4.4. Latin America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2021-2034
11.4.5. Latin America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
11.4.6. Latin America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2021-2034
11.4.7. Latin America Vascular Disrupting Agents Market revenue (US$ Million) by country, 2021-2034
11.5. Middle East & Africa
11.5.1. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) By Indications, (US$ Million) 2021-2034
11.5.2. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) By Therapeutic Area, (US$ Million) 2021-2034
11.5.3. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) By Molecule, (US$ Million) 2021-2034
11.5.4. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2021-2034
11.5.5. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
11.5.6. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2021-2034
11.5.7. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) by country, 2021-2034
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. AGC Biologics
12.2.2. Avid Bioservices
12.2.3. Bionomics
12.2.4. Beijing Shenogen Biomedical
12.2.5. Mateon Therapeutics
12.2.6. Myrexis
12.2.7. VBL Therapeutics
12.2.8. Steba biotech
12.2.9. BeyondSpring Pharmaceuticals
12.2.10. Immune Pharmaceuticals
12.2.11. Nereus Pharmaceuticals
12.2.12. Madrigal Pharmaceuticals, Inc.
12.2.13. Celgene Corporation
12.2.14. Bionomics Ltd.
12.2.15. Lees Pharmaceutical Holdings.
12.2.16. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們